Developing Life-Saving Medicines Through Cell Culture Technologies

In this expert interview, Dr. Martin Schilling of Evonik Health Care talks to Professor Michael Betenbaugh of Johns Hopkins University about the most exciting advances in cell culture-based production of biological drugs, collaborations between industry and academia, and future trends.

Topics covered include major advances in cell culture, the speed of development for mRNA and cell-culture based COVID-19 vaccines and monoclonal antibodies, the ever-accelerating rate of biological innovation, and an international academic-industrial collaboration initiative, AMBIC (Advanced Mammalian Biomanufacturing Innovation Center).

Dr. Martin Schilling, Director Cell Culture Ingredients at Evonik Health Care, is responsible for Evonik’s product portfolio of high-quality cell culture ingredients that are used to improve biopharma cell culture processes. He also manages Evonik’s innovation program that leverages existing core competencies in biotechnology, chemistry, and formulation development to address other emerging needs within the cell culture industry. Martin has a strong technical background in cell culture and industrial biotechnology and earned his Ph.D. in biochemistry from the Technical University of Munich in Germany in 2008.